摘要
吉列替尼(Gilteritinib,ASP2215)是一种新型、强效、高选择性、口服FLT3/AXL抑制剂[1]。相较于第一代FLT3抑制剂,具有较少的脱靶效应和较低的患者毒性。其每日1次单药疗法(≥80mg/d)在FLT3mut+复发性/难治性急性髓系白血病(acute myeloid leukemia,AML)患者中具有良好的抗白血病效应,2018年11月被美国FDA批准用于治疗FLT3基因突变引发的复发性或难治性AML,也是第一个FDA批准的第二代FLT3抑制剂[2-4]。2019年也被NCCN指南列为治疗难治复发性AML的第三种FLT3靶向药物。本文主要就吉列替尼治疗FLT3mut+AML的研究进展展开综述。
As a second-generation FLT3 inhibitor,gilteritinib was listed by the NCCN guidelines as the third FLT3 targeted drug for the treatment of relapsed acute myeloid leukemia(AML) in 2019.It is of great significance to understand and study the safety,tolerability,anti-leukemia activity and pharmacokinetics of gilteritinib in the treatment of AML with FLT3 mutations.It will be beneficial for the promotion and popularization of new targeted drugs,and thus enriching the treatment regimen of FLT3mut+ AML and increasing clinical benefit.This review focuses on the progress of gilteritinib in the treatment of FLT3mut+ AML.
作者
盘婉盈
李可昕
黄宇贤
PAN Wanying;LI Kexin;HUANG Yuxian
出处
《临床血液学杂志》
CAS
2020年第6期807-810,共4页
Journal of Clinical Hematology
基金
国家自然科学基金青年科学基金项目(No:81302372)。
